Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial-Reference-Cited by-同舟云学术

Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial

Published:2016-09-20 Issue:2 Volume:123 Page:253-262
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Loriot Yohann¹,Fizazi Karim¹,de Bono Johann S.²,Forer David³,Hirmand Mohammad³,Scher Howard I.⁴

Affiliation:

1. Department of Cancer Medicine, Gustave Roussy; Département de Médecine Oncologique, Université Paris-Saclay, Villejuif; France

2. The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research; Sutton United Kingdom

3. Medivation, Inc; San Francisco California

4. Memorial Sloan-Kettering Cancer Center; New York New York

Funder

Medivation, Inc.

Astellas Pharma, Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Globocan 2012 Estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 2015

3. Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint;Birtle;Expert Rev Anticancer Ther,2013

4. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China;Zhang;Asian J Androl,2009

5. Castration-resistant prostate cancer: AUA guideline;Cookson;J Urol,2013

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies;Cancers;2024-05-30

2. From biology to the clinic — exploring liver metastasis in prostate cancer;Nature Reviews Urology;2024-04-26

3. Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India;Applied Health Economics and Health Policy;2024-01-10

4. A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study);Therapeutic Advances in Medical Oncology;2024-01

5. Research trends and hotspots in prostate cancer associated exosome: a bibliometric analysis;Frontiers in Oncology;2023-11-21